NCT01658579View on ClinicalTrials.gov

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

HOE901-U300 (new formulation of insulin glargine)

DRUG

Lantus (insulin glargine)

Trial Locations (3)

55416

Investigational Site Number 840001, Minneapolis

92591

Investigational Site Number 840002, Temecula

97201-3098

Investigational Site Number 840003, Portland

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY